Explore
Validate
Learn
Immunohistochemistry
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [11]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB375-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Human TRAIL/TNFSF10 Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from ascites. Detects human TRAIL/TNFSF10 in direct ELISAs.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
P50591- Isotype
- IgG
- Antibody clone number
- 75411
- Vial size
- 100 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNFα in Castration-Resistant Prostate Cancer.
Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways.
Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities.
TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity.
TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor.
TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.
Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells.
A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation.
Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes.
Vickman RE, Yang J, Lanman NA, Cresswell GM, Zheng F, Zhang C, Doerge RW, Crist SA, Mesecar AD, Hu CD, Ratliff TL
Molecular cancer research : MCR 2019 Jun;17(6):1253-1263
Molecular cancer research : MCR 2019 Jun;17(6):1253-1263
Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways.
Tanzer MC, Khan N, Rickard JA, Etemadi N, Lalaoui N, Spall SK, Hildebrand JM, Segal D, Miasari M, Chau D, Wong WL, McKinlay M, Chunduru SK, Benetatos CA, Condon SM, Vince JE, Herold MJ, Silke J
Cell death and differentiation 2017 Mar;24(3):481-491
Cell death and differentiation 2017 Mar;24(3):481-491
Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI, Ungefroren H, Helm O, Voigt S, Alp G, Braun H, Hübner S, Dilchert J, Sebens S, Adam D, Kalthoff H, Trauzold A
Cellular signalling 2016 Nov;28(11):1652-62
Cellular signalling 2016 Nov;28(11):1652-62
Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities.
Tel J, Smits EL, Anguille S, Joshi RN, Figdor CG, de Vries IJ
Blood 2012 Nov 8;120(19):3936-44
Blood 2012 Nov 8;120(19):3936-44
TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity.
Kalb ML, Glaser A, Stary G, Koszik F, Stingl G
Journal of immunology (Baltimore, Md. : 1950) 2012 Feb 15;188(4):1583-91
Journal of immunology (Baltimore, Md. : 1950) 2012 Feb 15;188(4):1583-91
TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor.
Kavurma MM, Schoppet M, Bobryshev YV, Khachigian LM, Bennett MR
The Journal of biological chemistry 2008 Mar 21;283(12):7754-62
The Journal of biological chemistry 2008 Mar 21;283(12):7754-62
TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.
Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2008 Apr;28(4):253-63
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2008 Apr;28(4):253-63
Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells.
Krysov SV, Rowley TF, Al-Shamkhani A
Molecular cancer therapeutics 2007 Feb;6(2):703-11
Molecular cancer therapeutics 2007 Feb;6(2):703-11
A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation.
Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J, Trejdosiewicz LK
Cell death and differentiation 2006 Oct;13(10):1789-801
Cell death and differentiation 2006 Oct;13(10):1789-801
Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C, Mukhopadhyay S, Kovacs E, Medina R, Patel P, Catina TL, Campbell KS, Santoli D
Journal of leukocyte biology 2005 Aug;78(2):359-71
Journal of leukocyte biology 2005 Aug;78(2):359-71
Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes.
Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, Bitzer M
Cancer research 2003 May 15;63(10):2369-72
Cancer research 2003 May 15;63(10):2369-72
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Cytotoxicity Induced by TRAIL/TNFSF10 and Neutralization by Human TRAIL/TNFSF10 Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induces cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, cytotoxicity elicited by Recombinant Human TRAIL/TNFSF10 (12 ng/mL) is neutralized (green line) by increasing concentrations of Human TRAIL/TNFSF10 Monoclonal Antibody (Catalog # MAB375). The ND50 is typically 2-8 ng/mL.
